Overview
Non-Q wave myocardial infarction (NQMI) refers to myocardial infarction without diagnostic Q waves on the electrocardiogram, often representing a less extensive area of myocardial necrosis compared to Q-wave infarctions. It commonly occurs in the context of unstable angina and requires prompt management to prevent adverse outcomes 1.Diagnosis
Clinical Presentation: Typical symptoms of angina, ECG changes (ST-segment depression, T-wave inversion), and elevated cardiac biomarkers 1.
Electrocardiogram (ECG): Absence of diagnostic Q waves, presence of ST-segment changes or T-wave abnormalities 1.
Cardiac Biomarkers: Elevated troponin levels to confirm myocardial injury 1.
Imaging: Consider echocardiography or coronary angiography to assess myocardial function and coronary artery status 1.Management
Anticoagulation: Enoxaparin initiation with intravenous bolus (30 mg) followed by subcutaneous injections (1.0 mg/kg every 12 hours initially, then outpatient phase dosing: 40 mg for <65 kg, 60 mg for ≥65 kg) reduces death and ischemic events 1.
Antiplatelet Therapy: Dual antiplatelet therapy (e.g., aspirin plus a P2Y12 inhibitor) is standard 1.
Revascularization: Consider early revascularization (PCI or CABG) in high-risk patients 1.
Secondary Prevention: Lifestyle modifications, lipid management, blood pressure control, and consideration of beta-blockers and ACE inhibitors 1.Special Populations
Elderly: Management principles similar to younger adults, with careful consideration of bleeding risk with anticoagulants 1.
Comorbidities: Tailor anticoagulation and antiplatelet strategies considering coexisting conditions like renal impairment or bleeding risk 1.Key Recommendations
Use Enoxaparin for anticoagulation in patients with unstable angina/NQMI to reduce the risk of death, myocardial infarction, and urgent revascularization (Evidence: Strong) 1.
Initiate Dual Antiplatelet Therapy including aspirin and a P2Y12 inhibitor as part of initial management (Evidence: Strong) 1.
Consider Early Revascularization strategies (PCI or CABG) in high-risk patients to improve outcomes (Evidence: Moderate) 1.References
1 Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D et al.. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999. link